Dr. Colin Walsh joined NanoDimension as a part-time associate in 2014 and as a member of the life science investment team in 2015. He focuses on deal sourcing, due diligence, deal structuring and portfolio company management. He is a board observer of Emulate and Pulse Therapeutics.
Previously, Colin spent three years at Precision NanoSystems, a 5AM Ventures- and THP-backed biotech start-up from the labs of Dr. Pieter Cullis and Dr. Carl Hansen at UBC. There, he helped develop microfluidics-based instrumentation and processes for the manufacture of clinical nanomedicines as a lead scientist. He also held roles in product and business development, where he worked closely with management to define the strategy and direction of the business. In addition, he has served as a strategic and technical consultant for several biotech companies, with a focus on nanotechnology, drug delivery, and RNA therapeutics.
Colin earned his PhD in 2012 from The UC Berkeley – UCSF Graduate Program in Bioengineering, where he developed novel materials for nanoparticle-based RNA delivery as an NSF Graduate Research Fellow in the lab of Dr. Frank Szoka. Colin holds a Management of Technology certificate from the UC Berkeley Haas School of Business, and a dual BS with Honors in Chemical Engineering and Biochemistry from the University of Massachusetts, Amherst.